Article metrics

Download PDFPDF

894 A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to January 2024

AbstractFullPdf
Nov 2022288019
Dec 202266014
Jan 202368013
Feb 202384016
Mar 20234806
Apr 20238005
May 202372011
Jun 20234603
Jul 20233805
Aug 20233605
Sep 20232201
Oct 20231803
Nov 2023108012
Dec 20233206
Jan 20242801
Total10340120